referencias
  1. Lindholm LH, Ibsen H y cols. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002;20:1879–1886.
  2. Datos en archivo, MSD.
  3. Wachtell K, Lehto M, Gerdts E y cols. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE study. J Am Coll Cardiol 2005;45:712–719.



 
 

Antes de prescribir, consulte la  circular del producto completa.

† Marca(s) registrada(s) de E.I. du Pont de Nemours and Company, Wilmington, DE, EE.UU.